Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Front Endocrinol (Lausanne). 2024 Apr 15;15:1253832. doi: 10.3389/fendo.2024.1253832. eCollection 2024.
In recent years, with the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment, the toxicity associated with immunotherapy of ICIs has attracted more attention from scholars. Endocrine toxicity is the most likely immune-related adverse events (irAEs) and is often irreversible, posing a significant clinical treatment challenge.
In this study, bibliometric methods were used to analyze relevant literature in screening endocrine-related adverse events caused by ICIs in the Web of Science core collection database (WoSCC) and to summarize the status, research hot spots, and future trends in this field.
321 countries, 297 institutions, 365 authors, and 305 journals had published 671 English documents on endocrine adverse reactions of ICIs as of 1 December, 2022. The United States, Japan, and China were the top three countries with the most publications. The University of Texas MD Anderson Cancer Center, Harvard Medical School, and Memorial Sloan Kettering Cancer Center were the top three research institutions in terms of publication output. F Stephen Hodi, from the Dana-Farber Cancer Institute in the United States, contributed the largest number of publications. Frontiers in Oncology, which was the most widely distributed publication in the field. The main keywords or clusters identified that current research hotspots include the management of endocrine-related adverse events, hypophysitis, thyroid dysfunction, type I diabetes mellitus, and the impact of endocrine adverse events on survival of patients in this field.
The basic knowledge structure of the field of endocrine-related adverse events of ICIs, including publication trends, authors, institutions, countries, keywords, journals and publications, and cited documents, was visually analyzed in this bibliometric analysis. The research results comprehensively demonstrated the hot spots and future trends in the research field, as well as its broad prospects, thus providing a reference for the researchers.
近年来,随着免疫检查点抑制剂(ICI)在癌症治疗中的广泛应用,ICI 免疫治疗相关的毒性引起了学者们的更多关注。内分泌毒性是最有可能发生的免疫相关不良事件(irAEs),且往往是不可逆的,这给临床治疗带来了重大挑战。
本研究采用文献计量学方法,对 Web of Science 核心合集数据库(WoSCC)中筛选出的与 ICI 引起的内分泌相关不良事件相关的文献进行分析,总结该领域的现状、研究热点和未来趋势。
截至 2022 年 12 月 1 日,全球 321 个国家/地区、297 家机构、365 位作者和 305 种期刊共发表了 671 篇关于 ICI 内分泌不良反应的英文文献。美国、日本和中国是发表文献最多的前三个国家。在发表文献数量方面,美国德克萨斯大学 MD 安德森癌症中心、美国哈佛医学院和美国纪念斯隆凯特琳癌症中心位列前三位。来自美国丹娜-法伯癌症研究所的 F Stephen Hodi 发表的文献数量最多。发表文献最多的期刊是 Frontiers in Oncology。当前研究热点主要包括内分泌相关不良事件的管理、垂体炎、甲状腺功能障碍、I 型糖尿病以及内分泌不良事件对患者生存的影响等。
本研究通过文献计量学分析,直观地分析了 ICI 内分泌相关不良事件领域的基础知识结构,包括文献发表趋势、作者、机构、国家/地区、关键词、期刊和出版物以及被引文献等,全面展示了该研究领域的热点和未来趋势,以及其广阔的前景,为研究人员提供了参考。